Related Articles
The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR‑TKIs but is not an indication of acquired resistance to EGFR‑TKIs in NSCLC patients with EGFR mutations
Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status
Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC